BDX

Business Context and Reporting Period

This Form 10-Q covers Becton, Dickinson and Company (BD) for the quarterly and nine-month periods ended June 30, 2003. BD operates through three principal segments: BD Medical Systems, BD Clinical Laboratory Solutions, and BD Biosciences. The company reported strong revenue growth driven by international markets and the transition to safety-engineered products, though results were impacted by significant non-cash impairment charges in the Biosciences segment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 17% for the quarter and 13% for the nine months compared to the prior year. Organic growth (excluding currency) was approximately 11% for the quarter and 9% for the nine months.
• Segment Performance:
  • Medical Systems: Revenues up 19% (13% organic), driven by pharmaceutical systems (+40%) and safety-engineered products.
  • Clinical Lab: Revenues up 13% (8% organic), aided by strong sales of the BD ProbeTec ET molecular diagnostic platform.
  • Biosciences: Revenues up 14% (7% organic), driven by the new BD FACSAria cell sorter, though molecular biology reagent sales declined 13% due to reduced research spending.
• Profitability Impact: Operating margins declined from 16.6% to 15.0% for the quarter. This was primarily due to $34 million in non-cash charges recorded in the current quarter related to the write-down of intangible assets and inventory in the Biosciences segment. The prior year quarter included $11.6 million in special charges.
• Debt Structure: In April 2003, BD issued $400 million in new long-term notes ($200M at 4.55% due 2013 and $200M at 4.9% due 2018) and entered into interest rate swaps to manage exposure.

Guidance, Outlook, and Risks

• Restructuring Outlook: BD expects to achieve approximately $15 million in annual savings from its 2002 manufacturing restructuring program beginning in fiscal 2004. Savings from the 2000 restructuring continue to offset costs associated with the "Genesis" information systems upgrade.
• Capital Spending: Capital expenditures for fiscal 2003 are expected to be approximately $275 million.
• Dividends: The company declared a quarterly dividend of $0.10 per share.
• Key Risks and Contingencies:
  • Legal Proceedings: BD is involved in various litigation, including 523 claims related to latex glove exposure and a patent infringement suit by Retractable Technologies, Inc. (trial set for Feb 2004). Management believes outcomes will not be material but acknowledges uncertainty.
  • Market Risks: Risks include healthcare cost containment, pricing pressures, raw material costs, and the potential impact of the SARS epidemic.
  • Accounting Changes: BD is evaluating the impact of FIN 46 (consolidation of variable interest entities) effective July 1, 2003.

Investor Verification Checklist

• Impairment Charges: Verify the details of the $34 million non-cash charge in the Biosciences segment, specifically the $26.7 million write-down of the BD IMAGN instrument platform assets.
• Debt Covenants: Review the interest coverage ratio covenants associated with the $900 million syndicated credit facilities, one of which expires in August 2003.
• Latex Litigation: Monitor the status of the 523 latex exposure claims and the outcome of the Retractable Technologies patent trial scheduled for early 2004.
• Inventory Levels: Note the increase in inventory levels ($811M vs $698M prior year) driven by the build-up of blood glucose monitoring products; assess if this aligns with sales forecasts.
• Stock Repurchases: Confirm the remaining authorization of 7.4 million shares for repurchase under the January 2003 Board resolution.